Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV‐Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial

机译：在START（抗逆转录病毒治疗的战略时机）试验中HIV阳性参与者立即开始抗病毒治疗和延缓抗逆转录病毒治疗后心血管疾病危险因素的变化

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction HIV infection and certain antiretroviral therapy (ART) medications increase atherosclerotic cardiovascular disease risk, mediated, in part, through traditional cardiovascular disease risk factors.

机译：简介HIV感染和某些抗逆转录病毒疗法（ART）药物会增加动脉粥样硬化性心血管疾病的风险，这种风险部分是由传统的心血管疾病危险因素介导的。

著录项

期刊名称 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
作者
Jason V. Baker; Shweta Sharma; Amit C. Achhra; Jose Ignacio Bernardino; Johannes R. Bogner; Daniel Duprez; Sean Emery; Brian Gazzard; Jonathan Gordin; Greg Grandits; Andrew N. Phillips; Siegfried Schwarze; Elsayed Z. Soliman; Stephen A. Spector; Giuseppe Tambussi; Jens Lundgren;
展开▼
作者单位

展开▼
年(卷),期 2017(6),5
年度 2017
页码 e004987
总页数 23
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
antiretroviral therapy cholesterol HIV risk factor;

机译：抗逆转录病毒疗法;胆固醇;艾滋病毒;危险因素;

相似文献

外文文献
中文文献
专利

1. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial [J] . Kunisaki Ken M., Niewoehner Dennis E., Collins Gary, The lancet. Respiratory medicine. . 2016,第12期

机译：立即抗病毒治疗与延缓抗逆转录病毒治疗对艾滋病毒呈阳性的个体的肺部影响：在多中心，国际，随机，对照的抗逆转录病毒治疗战略时机中进行嵌套研究
2. Risk Factors for Low CD4(+) Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4(+) Counts > 500 Cells/mm(3): Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial [J] . Boatman Jeffrey A., Baker Jason V., Emery Sean, JAIDS: Journal of acquired immune deficiency syndromes . 2019,第1期

机译：低CD4（+）计数恢复的危险因素尽管参与者在抗逆转录病毒治疗和CD4（+）计数> 500细胞/ mm（3）中的病毒抑制：来自抗逆转录病毒治疗（开始）试验的战略时机的调查结果
3. Kidney disease in antiretroviral-naive HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial [J] . Achhra A. C., Mocroft A., Ross M. J., HIV medicine . 2015,第Suppla1期

机译：CD4计数高的初次使用抗逆转录病毒的HIV阳性成年人的肾脏疾病：INSIGHT抗逆转录病毒治疗的战略时机（START）试验中的肾脏疾病患病率和预测因素
4. The Effectiveness of an Antiretroviral Treatment (ARV) and a Highly Active Antiretroviral Therapy (HAART) on HIV/AIDS Epidemic Model [C] . Ummu Habibah, Ririt Andria Sari Basic Science International Conference . 2018

机译：抗逆转录病毒治疗（ARV）和高活性抗逆转录病毒治疗（HAART）对艾滋病毒/艾滋病流行病模型的有效性
5. An investigation of human and viral genetic factors influencing HIV disease progression and response to treatment in the era of highly active antiretroviral therapy (HAART). [D] . Brumme, Zabrina Lesley. 2006

机译：在高效抗逆转录病毒疗法（HAART）时代，对影响HIV疾病进展和对治疗反应的人类和病毒遗传因素的调查。
6. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre international randomised controlled Strategic Timing of Antiretroviral Treatment (START) trial [O] . Ken M Kunisaki, Dennis E Niewoehner, Gary Collins, -1

机译：立即抗病毒治疗与延迟抗艾滋病毒治疗对肺结核患者的肺部影响：在多中心国际随机对照的抗逆转录病毒治疗战略时机（START）试验中的嵌套亚研究
7. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial [O] . Kunisaki, KM, Niewoehner, DE, Collins, G, 2016

机译：立即抗病毒治疗与延迟抗艾滋病毒治疗对肺结核患者的肺部影响：在多中心，国际，随机，对照的抗逆转录病毒治疗战略时机（START）试验中的嵌套亚研究

Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV‐Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial

摘要

著录项

相似文献

相关主题

期刊订阅